Positive News SentimentPositive NewsNASDAQ:ELUT Elutia (ELUT) Stock Price, News & Analysis $1.16 +0.04 (+3.57%) Closing price 04:00 PM EasternExtended Trading$1.16 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Elutia Stock (NASDAQ:ELUT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Elutia alerts:Sign Up Key Stats Today's Range$1.10▼$1.1850-Day Range$0.98▼$1.2052-Week Range$0.50▼$2.64Volume75,010 shsAverage Volume150,773 shsMarket Capitalization$49.62 millionP/E Ratio1.35Dividend YieldN/APrice Target$6.00Consensus RatingModerate Buy Company Overview Elutia, Inc. is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors. The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions. Elutia’s platform may also have applications in acute respiratory distress and inflammatory diseases, and the company continues to explore partnerships to expand its pipeline and accelerate development timelines. Founded in 2015 and headquartered in New Haven, Connecticut, Elutia serves the U.S. market and is pursuing collaborations to support international expansion. Its management team brings together expertise in biopharmaceutical research, clinical development, and regulatory affairs, with a shared focus on advancing innovative therapies toward regulatory approval and commercialization.AI Generated. May Contain Errors. Read More Elutia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreELUT MarketRank™: Elutia scored higher than 70% of companies evaluated by MarketBeat, and ranked 266th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingElutia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialElutia has a consensus price target of $6.00, representing about 417.2% upside from its current price of $1.16.Amount of Analyst CoverageElutia has only been the subject of 1 research reports in the past 90 days.Read more about Elutia's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elutia is 1.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Elutia is 1.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.25.Price to Book Value per Share RatioElutia has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Elutia's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.46% of the float of Elutia has been sold short.Short Interest Ratio / Days to CoverElutia has a short interest ratio ("days to cover") of 0.76, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elutia has recently increased by 12.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElutia does not currently pay a dividend.Dividend GrowthElutia does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentElutia has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Elutia this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ELUT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Elutia to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elutia insiders have not sold or bought any company stock.Percentage Held by Insiders27.60% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Elutia's insider trading history. Receive ELUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elutia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELUT Stock News HeadlinesElutia Targets $1.5B Breast Reconstruction Market With Antibiotic MatrixMay 19, 2026 | americanbankingnews.comElutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 29 at 1:00 AM | InvestorPlace (Ad)Elutia Inc (ELUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Revenue ShiftsMay 15, 2026 | finance.yahoo.comElutia (ELUT) Q1 2026 Earnings TranscriptMay 15, 2026 | fool.comElutia Inc. (ELUT) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comElutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery MarketMay 14, 2026 | globenewswire.comElutia to Present at the 16th Annual LD Micro Invitational on May 18thMay 14, 2026 | globenewswire.comSee More Headlines ELUT Stock Analysis - Frequently Asked Questions How have ELUT shares performed this year? Elutia's stock was trading at $0.6927 at the beginning of 2026. Since then, ELUT shares have increased by 67.5% and is now trading at $1.16. How were Elutia's earnings last quarter? Elutia Inc. (NASDAQ:ELUT) posted its earnings results on Thursday, May, 14th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.02. The business had revenue of $3.11 million for the quarter, compared to analyst estimates of $3 million. Read the conference call transcript. When did Elutia IPO? Elutia (ELUT) raised $50 million in an initial public offering on Wednesday, October 7th 2020. The company issued 2,941,176 shares at $16.00-$18.00 per share. Who are Elutia's major shareholders? Top institutional shareholders of Elutia include AIGH Capital Management LLC (8.40%), Perkins Capital Management Inc. (1.77%), Rossmore Private Capital (0.28%) and Renaissance Technologies LLC (0.19%). Insiders that own company stock include Highcape Capital, LP, Matthew Ferguson, C Randal Mills, David Colpman and Brigid Makes. View institutional ownership trends. How do I buy shares of Elutia? Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elutia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elutia investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Jabil (JBL), Meta Platforms (META) and ServiceNow (NOW). Company Calendar Last Earnings5/14/2026Today5/29/2026Next Earnings (Estimated)8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ELUT's financial health is in the Green zone, according to TradeSmith. ELUT has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELUT CIK1708527 Webwww.elutia.com Phone240-247-1170Fax510-307-9896Employees180Year FoundedN/APrice Target and Rating Average Price Target for Elutia$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+417.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.86 Trailing P/E Ratio1.35 Forward P/E RatioN/A P/E GrowthN/ANet Income$53.38 million Net Margins312.09% Pretax Margin-136.52% Return on EquityN/A Return on Assets-53.97% Debt Debt-to-Equity RatioN/A Current Ratio2.05 Quick Ratio1.94 Sales & Book Value Annual Sales$12.29 million Price / Sales4.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book2.19Miscellaneous Outstanding Shares42,780,000Free Float30,976,000Market Cap$49.62 million OptionableNot Optionable Beta0.75 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ELUT) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
